KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Change in Cash: 2010-2025

Historic Change in Cash for Neogenomics (NEO) over the last 15 years, with Sep 2025 value amounting to $9.4 million.

  • Neogenomics' Change in Cash rose 36.01% to $9.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$197.9 million, marking a year-over-year decrease of 454.91%. This contributed to the annual value of $24.5 million for FY2024, which is 69.08% down from last year.
  • As of Q3 2025, Neogenomics' Change in Cash stood at $9.4 million, which was up 104.91% from -$191.5 million recorded in Q2 2025.
  • Over the past 5 years, Neogenomics' Change in Cash peaked at $372.5 million during Q1 2021, and registered a low of -$250.2 million during Q2 2021.
  • For the 3-year period, Neogenomics' Change in Cash averaged around -$9.0 million, with its median value being $9.4 million (2025).
  • Per our database at Business Quant, Neogenomics' Change in Cash skyrocketed by 1,330.45% in 2023 and then slumped by 926.34% in 2025.
  • Over the past 5 years, Neogenomics' Change in Cash (Quarterly) stood at -$26.9 million in 2021, then soared by 89.05% to -$2.9 million in 2022, then soared by 1,330.45% to $36.2 million in 2023, then tumbled by 86.15% to $5.0 million in 2024, then spiked by 36.01% to $9.4 million in 2025.
  • Its Change in Cash stands at $9.4 million for Q3 2025, versus -$191.5 million for Q2 2025 and -$20.8 million for Q1 2025.